Format

Send to:

Choose Destination
See comment in PubMed Commons below
Expert Opin Biol Ther. 2008 Feb;8(2):213-20. doi: 10.1517/14712598.8.2.213 .

Oncolytic measles virus strains in the treatment of gliomas.

Author information

  • 1Mayo Clinic, Molecular Medicine Department, 200 First Street SW, Rochester, MN 55905, USA.

Erratum in

  • Expert Opin Biol Ther. 2008 Jun;8(6):855. Myers, Rae [added]; Peng, Kah Whye [added]; Russell, Stephen J [added].

Abstract

BACKGROUND:

Recurrent gliomas have a dismal outcome despite use of multimodality treatment including surgery, radiation therapy and chemotherapy.

OBJECTIVE:

In this article the authors discuss potential applications of oncolytic measles virus strains as novel antitumor agents in the treatment of gliomas.

METHODS:

Important aspects of measles virus development as an anticancer therapeutic agent including engineering, retargeting and combination studies with other therapeutic modalities are discussed. The translational process that led to the first clinical trial of an engineered measles virus derivative in patients with recurrent glioblastoma multiforme is also described.

RESULTS/CONCLUSIONS:

Oncolytic measles virus strains hold promise as novel antitumor agents in the treatment of gliomas.

PMID:
18194077
[PubMed - indexed for MEDLINE]
PMCID:
PMC2756986
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare Icon for PubMed Central
    Loading ...
    Write to the Help Desk